Oncotarget’s Exemplification of the Various Breakthroughs in the Oncological Realm

The 21st Century has witnessed the publication of a series of medical journals, and one of the most notable journals of this kind is Oncotarget. With Impact Journals as its official publisher, this remarkable journal was established in 2010 with the aim of proffering to its readers an exclusive explanation and insights regarding the field of Oncology, the scientific study and treatment of tumours.Other than being an open-access journal that is available to the public at large, Oncotarget remains an outstanding journal as it is reviewed on weekly intervals by their proficient team of editors such as Mikhail Blagosklonny. Oncotarget’s exceptional insightfulness in the medical realm, especially in respect of treating tumours, was exemplified in an article authored by Wang-Yang Pu, entitled ‘Prediction of Cancer Progression in a Group of 73 Gastric Cancer Patients by circulating cell-free DNA.’

Bearing in mind the fact that gastric cancer is one of the most prevalent cancers, this article envisaged highlighting the process of circulating cell-free DNA within the human anatomy in order to predict gastric cancer progression rate therein. This prediction is premised on the fact that circulating cell-free DNA located in the plasma may contain some specific tumour makers and the fact that circulating cell-free DNA is an effective detector and predictor for malignant tumours in the human body.The article begins by enumerating a process that begins with the collection and assessment of plasma samples and clinical information from 40 healthy controls and 73 cancer patients.

Upon the performance of a qualitative Polymerase Chain Reaction (qPCR) using two sets of primers that facilitate the amplification of both long and short segments, the DNA integrity of the samples was calculated on the basis of the ratio of the long fragments to that of the short ones.The findings of this test as elaborated by the article made it sufficient to conclude that the Circulating Cell-free DNA is an effective molecular maker for which gastric cancer progression can be assessed and predicted. On the same breath, it is prudent to acknowledge Oncotarget’s immense effort to sensitize, educate, and proffer insights to the public regarding tumours and cancers. Their remarkable articles are certainly an exemplification of some of the great breakthroughs that have been made in the medical realm.

Eric Lefkofsky

Eric Lefkofsky started his career by selling carpets at the University of Michigan. Eric Lefkofsky is the co-founder and CEO of Tempus, a startup company that built an operating system to advance the treatment of cancer. He is also the chairman of Groupon and Uptake Technologies. He has also a trustee at Lurie children’s hospital in Chicago.

Cancer is an abnormal cell growth with the potential to spread to other parts of the body. In 2015 about 90.5 million people suffered from cancer. Cancer’s burden in society has become vast enough so that almost every person either knows or is related to someone who has suffered from cancer.

According to Eric Lefkofsy, Tempus is an end-to-end solution. His objective is to collect huge amounts of data through its collaborations with academic institutions and hospitals. Its services are two-fold, namely to provide gene-sequencing tests at its River North headquarters in a laboratory, and to provide physicians software-based solutions that give a rapid comparison of a patient’s genetic profile to its database.

Lefkofsky also serves as a Trustee of Lurie Children’s Hospital situated in Chicago, The Art Institute of Chicago, World Business Chicago and The Museum of Science and Industry.

Tempus has developed an operating system or software data platform providing analysis of large volumes of clinical and molecular data. It is working with systems of hospitals such as Northwestern, the University of Michigan, the Mayo Clinic, the Cleveland Clinic, the UC Davis Comprehensive Cancer Center and Duke University School of Medicine.

The Tempus website shows it has helped doctors and professionals of health care, make decisions based on the data they have gathered. Tempus also says it has been using “cutting-edge genomic sequencing and analysis methods” and helping doctors for a better understanding of patient’s cancer.

Tempus founded in 2015, has since grown to a 200 employee company and is one of the top ten Chicago tech startups. Tempus shares the ranking with companies such as Avant, Outcome Health, SMS Assist, IRI, SpringCM and Analyte Health. Recently Tempus has secured about $70 million in funding and which it has used to provide services to patients.